Literature DB >> 23856250

Survivin-3B potentiates immune escape in cancer but also inhibits the toxicity of cancer chemotherapy.

Frédérique Végran1, Romain Mary, Anne Gibeaud, Céline Mirjolet, Bertrand Collin, Alexandra Oudot, Céline Charon-Barra, Laurent Arnould, Sarab Lizard-Nacol, Romain Boidot.   

Abstract

Dysregulation in patterns of alternative RNA splicing in cancer cells is emerging as a significant factor in cancer pathophysiology. In this study, we investigated the little known alternative splice isoform survivin-3B (S-3B) that is overexpressed in a tumor-specific manner. Ectopic overexpression of S-3B drove tumorigenesis by facilitating immune escape in a manner associated with resistance to immune cell toxicity. This resistance was mediated by interaction of S-3B with procaspase-8, inhibiting death-inducing signaling complex formation in response to Fas/Fas ligand interaction. We found that S-3B overexpression also mediated resistance to cancer chemotherapy, in this case through interactions with procaspase-6. S-3B binding to procaspase-6 inhibited its activation despite mitochondrial depolarization and caspase-3 activation. When combined with chemotherapy, S-3B targeting in vivo elicited a nearly eradication of tumors. Mechanistic investigations identified a previously unrecognized 7-amino acid region as responsible for the procancerous properties of survivin proteins. Taken together, our results defined S-3B as an important functional actor in tumor formation and treatment resistance. ©2013 AACR.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23856250     DOI: 10.1158/0008-5472.CAN-13-0036

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  7 in total

Review 1.  Survivin splice variants and their diagnostic significance.

Authors:  Nand K Sah; Chandrabhan Seniya
Journal:  Tumour Biol       Date:  2015-08-06

2.  Survivin-3B promotes chemoresistance and immune escape by inhibiting caspase-8 and -6 in cancer cells.

Authors:  Frédérique Végran; Romain Boidot
Journal:  Oncoimmunology       Date:  2013-10-09       Impact factor: 8.110

Review 3.  Alternative RNA structure-coupled gene regulations in tumorigenesis.

Authors:  Feng-Chi Chen
Journal:  Int J Mol Sci       Date:  2014-12-29       Impact factor: 5.923

Review 4.  Function, clinical application, and strategies of Pre-mRNA splicing in cancer.

Authors:  Cuixia Di; Qianjing Zhang; Yuhong Chen; Yupei Wang; Xuetian Zhang; Yang Liu; Chao Sun; Hong Zhang; Jörg D Hoheisel
Journal:  Cell Death Differ       Date:  2018-11-21       Impact factor: 15.828

Review 5.  Alternative Splicing in Cancer and Immune Cells.

Authors:  Antoine Bernard; Romain Boidot; Frédérique Végran
Journal:  Cancers (Basel)       Date:  2022-03-28       Impact factor: 6.639

6.  Early diagnostic value of survivin and its alternative splice variants in breast cancer.

Authors:  Salma Khan; Heather Ferguson Bennit; David Turay; Mia Perez; Saied Mirshahidi; Yuan Yuan; Nathan R Wall
Journal:  BMC Cancer       Date:  2014-03-12       Impact factor: 4.430

7.  Comprehensive Analysis of Alternative Splicing Signature in Gastric Cancer Prognosis Based on The Cancer Genome Atlas (TCGA) and SpliceSeq Databases.

Authors:  Xiaohu Cheng; Xianghua Li; Yimei Gu; Lianbang Zhou; Jingjing Tang; Xiang Dai; Heng Jiang; Yang Huang; Yingfeng Zhang; Tongtong Xu; Zhining Liu; Qihong Zhao
Journal:  Med Sci Monit       Date:  2020-11-21
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.